Sznol M - Search Results

1

Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy.

Flies DB, Sandler BJ, Sznol M, Chen L. Flies DB, et al. Among authors: sznol m. Yale J Biol Med. 2011 Dec;84(4):409-21. Yale J Biol Med. 2011. PMID: 22180678 Free PMC article. Review.

2

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Topalian SL, et al. Among authors: sznol m. N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2. N Engl J Med. 2012. PMID: 22658127 Free PMC article. Clinical Trial.

3

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.

Sznol M, Chen L. Sznol M, et al. Clin Cancer Res. 2013 Mar 1;19(5):1021-34. doi: 10.1158/1078-0432.CCR-12-2063. Clin Cancer Res. 2013. PMID: 23460533 Free PMC article.

4

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response.

Sznol M, Chen L. Sznol M, et al. Clin Cancer Res. 2013 Oct 1;19(19):5542. doi: 10.1158/1078-0432.CCR-13-2234. Epub 2013 Sep 18. Clin Cancer Res. 2013. PMID: 24048329 Free PMC article. No abstract available.

5

Programmed death ligand-1 expression in non-small cell lung cancer.

Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL. Velcheti V, et al. Among authors: sznol m. Lab Invest. 2014 Jan;94(1):107-16. doi: 10.1038/labinvest.2013.130. Epub 2013 Nov 11. Lab Invest. 2014. PMID: 24217091 Free PMC article.

6

Blockade of the B7-H1/PD-1 pathway as a basis for combination anticancer therapy.

Sznol M. Sznol M. Cancer J. 2014 Jul-Aug;20(4):290-5. doi: 10.1097/PPO.0000000000000056. Cancer J. 2014. PMID: 25098290 Review.

7

Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.

Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, Dhodapkar KM. Das R, et al. Among authors: sznol m. J Immunol. 2015 Feb 1;194(3):950-9. doi: 10.4049/jimmunol.1401686. Epub 2014 Dec 24. J Immunol. 2015. PMID: 25539810 Free PMC article.

8

Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.

Kluger HM, Zito CR, Barr ML, Baine MK, Chiang VL, Sznol M, Rimm DL, Chen L, Jilaveanu LB. Kluger HM, et al. Among authors: sznol m. Clin Cancer Res. 2015 Jul 1;21(13):3052-60. doi: 10.1158/1078-0432.CCR-14-3073. Epub 2015 Mar 18. Clin Cancer Res. 2015. PMID: 25788491 Free PMC article.

9

Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy.

Hughes J, Vudattu N, Sznol M, Gettinger S, Kluger H, Lupsa B, Herold KC. Hughes J, et al. Among authors: sznol m. Diabetes Care. 2015 Apr;38(4):e55-7. doi: 10.2337/dc14-2349. Diabetes Care. 2015. PMID: 25805871 Free PMC article. No abstract available.

10

Cancer Immunotherapy: Past Progress and Future Directions.

Atkins MB, Sznol M. Atkins MB, et al. Among authors: sznol m. Semin Oncol. 2015 Aug;42(4):518-22. doi: 10.1053/j.seminoncol.2015.05.001. Epub 2015 Jun 3. Semin Oncol. 2015. PMID: 26320057 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

240 results

Search Page